Varlilumab  (Synonyms: 伐立鲁单抗; CDX-1127)

Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors^[1][2].

TNFRSF7/CD27

Varlilumab (300 μg; 腹腔注射; 两次) 在接种 E.G7 肿瘤的 hCD27^+/+mCD27^-/-小鼠中，可延长小鼠的中位生存期且有较高的治愈率^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

939  [NCBI]

P26842

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145 kDa

1393344-72-3

无菌粉末

White to off-white

伐立鲁单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Stephen M Ansell, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020 May 12;4(9):1917-1926.  [Content Brief]

  [2]. Wasiuk A, et al. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice. Cancer Immunol Immunother. 2022 Jan;71(1):97-109.  [Content Brief]